Subsequent neoplasms in childhood cancer survivors
Language English Country Netherlands Media print-electronic
Document type Journal Article, Research Support, Non-U.S. Gov't
PubMed
32682319
DOI
10.1016/j.canep.2020.101779
PII: S1877-7821(20)30113-2
Knihovny.cz E-resources
- Keywords
- Genetic syndromes with increased risk of cancer, Long-term childhood cancer survivors, Subsequent benign neoplasm, Subsequent malignant neoplasm, Subsequent non-melanoma skin cancer,
- MeSH
- Child MeSH
- Adult MeSH
- Incidence MeSH
- Cohort Studies MeSH
- Humans MeSH
- Survival Rate MeSH
- Adolescent MeSH
- Neoplasms complications pathology therapy MeSH
- Cancer Survivors statistics & numerical data MeSH
- Prognosis MeSH
- Risk Factors MeSH
- Neoplasms, Second Primary epidemiology etiology pathology MeSH
- Check Tag
- Child MeSH
- Adult MeSH
- Humans MeSH
- Adolescent MeSH
- Male MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Geographicals
- Czech Republic epidemiology MeSH
OBJECTIVES: The aim of the study was to characterize subsequent neoplasm (SN) (malignant (SMN), benign (BSNs), and non-melanoma skin cancer (NMSC)) treated previously for a childhood solid malignant tumor at the Department of Pediatric Hematology and Oncology, Motol University Hospital, Prague. METHOD: We evaluated a cohort of 4059 childhood cancer survivors treated between 1975 and 2018. RESULTS: From 4059 survivors, 170 (4.3 %) developed at least one SMN - 193 SMNs in 170 survivors, 21 of them (0.5 % of all survivors) had two or more SMNs and 34 of them (0.8 %) had one SMN and one or more BSNs. Mortality for an SMN was 38.2 % i.e. 1.6 % of all survivors. The most frequent SMNs were thyroid carcinoma (37, 19.2 %), tumors of the central nervous system (25, 13.0 %), soft tissue sarcoma (23, 11.9 %), breast carcinoma (19, 9.8 %), and leukemia (11, 5.7 %). Genetic syndromes were present in 25 patients with SMNs (14.7 %) and in 16 patients with only BSNs (13.4 %). SMNs usually developed in second decade or later after finishing of therapy. We observed some not well known risk factors of SNs e.g. spinal irradiation or131-I metaiodobenzylguanidine radiotherapy in 2 cases of secondary thyroid cancer, cyclophosphamide therapy in all 8 cases of secondary urinary bladder sarcoma or 4 from 7 SNMSC developed SMN. CONCLUSIONS: We confirmed data from previous studies of SNs and observed some not so well known risk factors. Our results and the literature show that the incidence of SMNs is 3-10 % of survivors and is associated with high mortality.
References provided by Crossref.org
